Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic
- Author:
My Dung HOANG
1
;
Sung Hoon JUNG
;
Hyun Ju LEE
;
Youn Kyung LEE
;
Thanh Nhan NGUYEN-PHAM
;
Nu Ri CHOI
;
Manh Cuong VO
;
Seung Shin LEE
;
Jae Sook AHN
;
Deok Hwan YANG
;
Yeo Kyeoung KIM
;
Hyeoung Joon KIM
;
Je Jung LEE
Author Information
- Publication Type:Review
- Keywords: Multiple myeloma; Dendritic cells; Immunotherapy
- MeSH: Dendritic Cells; Humans; Immunotherapy; Multiple Myeloma; Stem Cell Transplantation; T-Lymphocytes, Cytotoxic
- From:Chonnam Medical Journal 2015;51(1):1-7
- CountryRepublic of Korea
- Language:English
- Abstract: Although the introduction of stem cell transplantation and novel agents has improved survival, multiple myeloma (MM) is still difficult to cure. Alternative approaches are clearly needed to prolong the survival of patients with MM. Dendritic cell (DC) therapy is a very promising tool immunologically in MM. We developed a method to generate potent DCs with increased Th1 polarization and migration ability for inducing strong myeloma-specific cytotoxic T lymphocytes. In this review, we discuss how the efficacy of cancer immunotherapy using DCs can be improved in MM.
